Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105 · View on ClinicalTrials.gov ↗
Study Summary
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutikizumab. Participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. Around 120 participants will be enrolled in the study at approximately 40 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Lutikizumab
- DRUG Risankizumab
Study Locations (20)
Florida
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085 — Avon Park
- Clinical Research Of West Florida - Phase I Unit /ID# 273198 — Clearwater
- HMD Research LLC /ID# 273086 — Orlando
- West Broward Rheumatology Associates /ID# 272892 — Tamarac
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199 — Tampa
Texas
- Tekton Research - West Gate /ID# 272765 — Austin
- Accurate Clinical Research - Houston /ID# 272754 — Houston
- Tekton Research, LLC /ID# 272901 — San Antonio
- Dynamed Clinical Research - Tomball /ID# 272760 — Tomball
Illinois
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 — Skokie
- Willow Rheumatology and Wellness, PLLC /ID# 277354 — Willowbrook
California
- Newport Huntington Medical Group /ID# 272764 — Huntington Beach
Maryland
- Klein And Associates /ID# 272829 — Hagerstown
Ohio
- Paramount Medical Research and Consulting /ID# 272757 — Middleburg Heights
Pennsylvania
- Altoona Center For Clinical Research /ID# 272593 — Duncansville
Tennessee
- Private Practice - Dr. Ramesh C. Gupta I /ID# 272897 — Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-04-11 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06865105
The ClinicalTrials.gov registry entry for NCT06865105 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions — of which Lutikizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06865105 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Texas, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06865105 about?
NCT06865105 is a clinical study titled "Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis". Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies th...
What is the current status of trial NCT06865105?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-04-11. Estimated completion is 2028-01.
What conditions does trial NCT06865105 study?
This clinical trial studies the following conditions: Psoriatic Arthritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06865105?
The interventions under investigation include: Lutikizumab (DRUG), Risankizumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06865105?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06865105 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.